|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
146,000,000 |
Market
Cap: |
15.86(B) |
Last
Volume: |
1,605,892 |
Avg
Vol: |
1,353,529 |
52
Week Range: |
$92.79 - $209.935 |
|
Level
I Sector: |
Information Technology |
Level
II Sector: |
Electronics |
Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 11.4 |
Insider 3/6 Months : 12 |
|
Guru Rank Number : 691 |
Guru Rank Value : 2.3 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,330 |
7,330 |
7,330 |
Total Buy Value |
$0 |
$991,672 |
$991,672 |
$991,672 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
0 |
0 |
1,815 |
22,740 |
Total Sell Value |
$0 |
$0 |
$314,105 |
$4,648,975 |
Total People Sold |
0 |
0 |
2 |
3 |
Total Sell Transactions |
0 |
0 |
4 |
17 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ronaghi Mostafa |
Sr VP & CTO |
|
2018-11-05 |
4 |
D |
$324.14 |
$386,699 |
D/D |
(1,193) |
69,612 |
|
- |
|
Van Oene Mark |
SVP Chief Commercial Officer |
|
2018-11-05 |
4 |
D |
$324.14 |
$394,803 |
D/D |
(1,218) |
9,073 |
|
- |
|
Van Oene Mark |
SVP Chief Commercial Officer |
|
2018-11-05 |
4 |
AS |
$323.42 |
$2,228,950 |
D/D |
(6,835) |
10,291 |
|
- |
|
Van Oene Mark |
SVP Chief Commercial Officer |
|
2018-11-05 |
4 |
OE |
$29.44 |
$176,640 |
D/D |
6,000 |
17,126 |
|
- |
|
Hampton Malcolm Garret |
EVP Clinical Genomics Group |
|
2018-11-05 |
4 |
D |
$324.14 |
$82,007 |
D/D |
(253) |
6,200 |
|
- |
|
Stapley Marc |
EVP Strategy & Corp Developmt |
|
2018-11-05 |
4 |
D |
$324.14 |
$513,114 |
D/D |
(1,583) |
6,957 |
|
- |
|
Dadswell Charles |
Sr VP & General Counsel |
|
2018-11-05 |
4 |
D |
$324.14 |
$258,015 |
D/D |
(796) |
6,172 |
|
- |
|
Samad Samer Abdul |
Sr. VP and CFO |
|
2018-11-05 |
4 |
D |
$324.14 |
$41,166 |
D/D |
(127) |
3,304 |
|
- |
|
Desouza Francis A |
President and CEO |
|
2018-11-01 |
4 |
AS |
$309.39 |
$652,788 |
D/D |
(2,100) |
70,235 |
|
- |
|
Epstein Robert S |
Director |
|
2018-11-01 |
4 |
AS |
$311.86 |
$419,764 |
D/D |
(1,346) |
5,101 |
|
- |
|
Epstein Robert S |
Director |
|
2018-11-01 |
4 |
OE |
$51.17 |
$51,170 |
D/D |
1,000 |
6,447 |
|
- |
|
Flatley Jay T |
Director |
|
2018-10-24 |
4 |
AS |
$310.58 |
$1,024,914 |
D/D |
(3,300) |
382,304 |
|
- |
|
Ronaghi Mostafa |
Sr VP & CTO |
|
2018-10-10 |
4 |
AS |
$305.22 |
$3,118,424 |
D/D |
(10,000) |
70,805 |
|
- |
|
Ronaghi Mostafa |
Sr VP & CTO |
|
2018-10-10 |
4 |
OE |
$37.04 |
$370,400 |
D/D |
10,000 |
80,805 |
|
- |
|
Flatley Jay T |
Director |
|
2018-10-10 |
4 |
AS |
$321.58 |
$1,061,214 |
D/D |
(3,300) |
385,604 |
|
- |
|
Epstein Robert S |
Director |
|
2018-10-01 |
4 |
AS |
$369.15 |
$496,876 |
D/D |
(1,346) |
5,447 |
|
- |
|
Epstein Robert S |
Director |
|
2018-10-01 |
4 |
OE |
$51.17 |
$51,170 |
D/D |
1,000 |
6,793 |
|
- |
|
Desouza Francis A |
President and CEO |
|
2018-10-01 |
4 |
AS |
$369.19 |
$776,183 |
D/D |
(2,100) |
72,335 |
|
- |
|
Flatley Jay T |
Director |
|
2018-09-26 |
4 |
AS |
$360.81 |
$1,190,673 |
D/D |
(3,300) |
388,904 |
|
- |
|
Flatley Jay T |
Director |
|
2018-09-12 |
4 |
AS |
$351.66 |
$1,160,478 |
D/D |
(3,300) |
392,204 |
|
- |
|
Ronaghi Mostafa |
Sr VP & CTO |
|
2018-09-10 |
4 |
AS |
$343.66 |
$3,470,709 |
D/D |
(10,000) |
70,805 |
|
- |
|
Ronaghi Mostafa |
Sr VP & CTO |
|
2018-09-10 |
4 |
OE |
$37.04 |
$370,400 |
D/D |
10,000 |
80,805 |
|
- |
|
Epstein Robert S |
Director |
|
2018-09-07 |
4 |
AS |
$345.14 |
$464,558 |
D/D |
(1,346) |
5,793 |
|
- |
|
Epstein Robert S |
Director |
|
2018-09-07 |
4 |
OE |
$51.17 |
$51,170 |
D/D |
1,000 |
7,139 |
|
- |
|
Stapley Marc |
EVP Strategy & Corp Developmt |
|
2018-09-04 |
4 |
AS |
$351.62 |
$352,054 |
D/D |
(1,000) |
8,516 |
|
- |
|
1655 Records found
|
|
Page 25 of 67 |
|
|